The purpose of this article is to discuss the pharmacological causes of pediatric Clostridioides difficile infection (CDI) and the treatment options available to clinicians. The authors identify antibiotic classes and antacids and how they interfere with normal gastrointestinal processes to cause CDI. In addition, the treatment algorithm for pediatric patients, which differs slightly from adults, is presented. Choosing the appropriate medication is imperative in reducing symptoms, recurrence, and optimizing treatment of CDI. This article will discuss the medications that contribute to CDI and not cover infectious causes or structural causes.
BartlettJ. G. (2006). Narrative review: The new epidemic of Clostridium difficile-associated enteric disease. Annals of Internal Medicine, 145(10), 758–764. 10.7326/0003-4819-145-10-200611210-00008
2.
BrittonR. A., & YoungV. B. (2014). Role of the intestinal microbiota in resistance to colonization by Clostridium difficile. Gastroenterology, 146(6), 1547–1553. 10.1053/j.gastro.2014.01.059
3.
JohnsonS., LavergneV., SkinnerA. M., Gonzales-LunaA. J., GareyK. W., KellyC. P., & WilcoxM. H. (2021). Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused update guidelines on management of Clostridioides difficile infection in adults. Clinical Infectious Diseases, 73, e1044–e1029. 10.1093/cid/ciab549
4.
KhannaS., BaddourL. M., HuskinsW. C., KammerP. P., FaubionW. A., ZinsmeisterA. R., HarmsenW. S., & PardiD. S. (2013). The epidemiology of Clostridium difficile infection in children: A population-based study. Clinical Infectious Diseases, 56(10), 1401–1406. 10.1093/cid/cit075
5.
McDonaldL. C., CoignardB., DubberkeE., SongX., HoranT., & KuttyP. K., Ad Hoc Clostridium difficile Surveillance Working Group (2007). Recommendations for surveillance of Clostridium difficile-associated disease. Infection Control & Hospital Epidemiology, 28(2), 140–145. 10.1086/511798
6.
PascaronR.in this issue add….
7.
PatilR., & BlankenshipL. (2013). Proton pump inhibitors and Clostridium difficile infection: Are we propagating an already rapidly growing healthcare problem?Gastroenterology Research, 6(5), 171–173. 10.4021/gr575w
8.
RaoS., KupferY., PagalaM., ChapnickE., & TesslerS. (2011). Systemic absorption of oral vancomycin in patients with Clostridium difficile infection. Scandinavian Journal of Infectious Diseases, 43(5), 386–388. 10.3109/00365548.2010.544671
9.
SteelB. J., & WhartonC. (2020). Metronidazole and alcohol. British Dental Journal, 229, 150–151. 10.1038/s41415-020-2012-x
10.
Tschudin-SutterS., TammaP. D., MilstoneA. M., & PerlT. M. (2014). Predictors of first recurrence of Clostridium difficile infections in children. Pediatric Infectious Disease Journal, 4, 414–416. 10.1097/INF.0000000000000108
